CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

Part of paid clinical trials in Houston, Texas.

Sponsor
Cyclacel Pharmaceuticals, Inc.
Study ID
NCT04017546
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CYC065 — DRUG
    intravenous infusion
  • Venetoclax — DRUG
    oral capsule

Study Details

A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory AML or MDS

Key Dates

Start date
Aug 2, 2019
Status verified
Sep 2024
Primary completion
Nov 15, 2022
Completion
Apr 5, 2023

Study Design

Enrollment
14 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: CYC065 and venetoclax
    CYC065 will be administered intravenously via 4-hour infusion on Day 1 and Day 15. Venetoclax will be taken daily on Day 1 through Day 15. One cycle will be 28 days or 4 weeks.

Primary Outcome Measure

Maximum tolerated dose (MTD) [ Time Frame: At the end of cycle 1 (each cycle is 28 days) ]

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
MD Anderson Cancer Center· Houston, TX

Related Studies